Noboru Yamamoto

65PUBLICATIONS
292CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (65)

|Oct 29, 2026
Longitudinal plasma osimertinib concentrations during treatment in patients with EGFR-mutant NSCLC: a prospective real-world study.

|Sep 22, 2026
Comprehensive Genomic Profiling Beyond Driver Testing in Non-Squamous Non-Small Cell Lung Cancer With Known Drivers.

|Aug 27, 2026
A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors.

|Jul 07, 2026
Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort.

|Jun 30, 2026
A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumors.

|Jun 29, 2026
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer.

Pageof 11

Frequent Collaborators

21 joint publications

Takafumi Koyama

11 joint publications

Kan Yonemori

10 joint publications

Tatsuya Yoshida

10 joint publications

Jun Sato